Role of Oxidative Stress in various stages of Psoriasis

Fearoz Khan1, Zahoor Ahmed2, Hajira Ishaq3, Sadia Azam Khan4, Mohammad Iqbal5, Mohammad Tayyab Ahmad6

1Department of Medicine, Bolan University of Medical & Health Sciences, Quetta.
2Department of Biochemistry, Khyber Medical College, Peshawar.
3Assistant Professor, Department of Biochemistry, Khyber Medical College, Peshawar.
4Assistant Professor, Poonch Medical College, Rawlakot, Azad Jammu & Kashmir.
3Assistant Professor, Department of Biochemistry, Khyber Medical College, Peshawar.
6BDS Scholar, Rehman College of Dentistry, Peshawar.

Author’s Contribution
1.2.3 Conception of study
6.7 Experimentation/Study conduction
3.4 Analysis/Interpretation/Discussion
1.2.3.4.5 Manuscript Writing
2.5 Critical Review

Corresponding Author
Dr. Zahoor Ahmed,
Department of Biochemistry,
Khyber Medical College,
Peshawar
Email: zakhan70@yahoo.co.uk

Cite this Article: Khan, F., Ahmed, Z., Ishaq, H., Khan, S.A., Iqbal, M., Ahmad, M.T., Umar, M. Role of Oxidative Stress in various stages of Psoriasis. Journal of Rawalpindi Medical College. 30 Dec. 2020; 24(4): 412-416.
DOI: https://doi.org/10.37939/jrmc.v24i4.1500

Conflict of Interest: Nil
Funding Source: Nil

Access Online:

Abstract

Introduction: Psoriasis is a chronic inflammatory, immune-mediated, provocative, and challenging skin condition. It is a non-contagious but debilitating disease and a leading cause of socioeconomic burden on the health system.

Objective: To evaluate the role of antioxidant levels, lipid peroxidation status, and lipid profile in the etiology and degree of severity of psoriatic illness among psoriasis patients presenting in the Dermatology Department.

Material and Methods: One hundred and twenty cases (n=130) of already diagnosed psoriasis patients were randomly and fifty healthy matched controls (n=50) of the same age and gender were included from the general population for comparison. Lipid profiles including serum total cholesterol, TG, HDL-c, and LDL-c levels were measured by enzyme colorimetric analysis on Micro Lab 300 (Merck & Germany). Antioxidant status SOD and lipid peroxidation status MDA was measured by the ELISA technique. Statistical analysis was performed using SPSS software Version 16. In this analysis, a “p” value of less than 0.05 was considered to be significant.

Results: The study showed significantly elevated levels of MDA, serum TG, total cholesterol, and LDL-c levels in psoriatic patients in comparison with controls, whereas SOD levels and HDL-c levels were found to be significantly lower in psoriatic patients as compared to normal healthy matched controls.

Conclusion: The findings of this study support the hypothesis that an imbalance in the oxidant-antioxidant system may play a role in the etiology of psoriasis and the degree of severity of its presentation. The study also concluded that dyslipidemia was an observed risk factor for the development of cardiovascular diseases in psoriatic patients.

Keywords: Oxidative Stress, Psoriasis, Superoxide Dismutase, Lipid Peroxidation, Malondialdehyde.
Introduction

Psoriasis is a chronic inflammatory, immune-mediated, provocative, and challenging skin condition. It is a non-contagious but debilitating disease and a leading cause of socioeconomic burden on the health system. It is characterized by red patchy lesions with grey, silvery whitish lines. Psoriatic rash classically presents on elbows, scalp, knees, nails, joints, and other parts of the body that may often be painful and pruritic when severe. Skin cells multiply and normally as they get older they shed off and are replaced by new cells; whereas, in psoriasis, skin cell production is increased many folds. Psoriasis can be classified as psoriasis vulgaris, guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis.

Psoriasis affects around 2% population of the world. According to the World Health Organization, about 125 million people around the world suffer from this disease, and among them only about half of the new cases are reported annually. Around 4.6% of the American population is affected by psoriasis, lower figures are found among Indians (0.7%) whereas significantly higher prevalence rates have been reported in Kazakhstan.

Psoriasis is an idiopathic clinical syndrome with multi-organ involvement. It has been postulated to be strongly associated with the abnormalities in essential fatty acid metabolism, lymphokine secretion, and oxidative stress/oxygen-related stress. New evidence has proposed that elevated reactive oxygen species (ROS) generation and reduced function of the antioxidant system may play a vital role in the pathophysiology of this disease. Dyslipidemia has been detected in the earlier stages of the development of psoriasis.

Psoriasis is a multi-factorial illness determined by both genetic and environmental influences; also associated with it are abnormal lipid profile, a rise in oxidative stress, and decreased antioxidant capacity. Scientific evidence strongly suggests an association of psoriasis with risk factors including hypertension, obesity, and diabetes mellitus, etc.

Chronic inflammation, which is a characteristic feature of psoriasis, may have a crucial role in the development and progression of dyslipidemia. An increase in ROS production during the inflammatory process in psoriasis may result in a reduction of antioxidant mechanisms that lead to lipid peroxidation.

Psoriasis presents with abnormalities in lipid profile, depletion of antioxidants defense mechanism with enhanced lipid peroxidation that in turn promote atherogenesis. Hence we have attempted to evaluate serum lipid profile, serum antioxidant levels, and lipid peroxidation status of psoriasis patients.

Materials and Methods

The present research was carried out as a case-control study, carried out in the Department of Biochemistry, Basic Medical Sciences Institute (BMSI) Jinnah Post Graduate Medical Centre (JPMC) Karachi in collaboration with the Department of Biochemistry, Khyber Medical College, Peshawar. The study duration was 9 months after its approval from concerned authorities. Ethical approval was obtained from the Ethical Review Committee of BMSI, JPMC Karachi. Informed consent was obtained from all participants taking part in the study. Proposed performa was used to collect the baseline data including age, gender, occupation, the ethnicity of the participants. Detailed medical history and relevant investigations were carried out as part of the methodology. Healthy individuals were matched as controls for comparison.

Inclusion Criteria: Diagnosed psoriatic patients were recruited in the study from the Department of Dermatology JPMC Karachi.

Exclusion Criteria: Those who were found to be alcoholics, smokers, hypothyroid, patients with liver disease or kidney disease, other skin diseases, and those who refused to be a part of the study were excluded.

Laboratory investigations e.g. lipid profile including serum total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) were tested by enzymatic colorimetric method on Micro Lab 300 (Merck & Germany). Antioxidant status was measured using superoxide dismutase (SOD) and lipid peroxidation status using malondialdehyde (MDA) assay was carried out by ELISA method. Non-probability purposive sampling techniques were used in this study. Blood samples of subjects who fulfilled the criteria were collected after an overnight fast of 10-12 hours. A strictly pre-defined protocol was used for sample collection, storage, and analysis.

Statistical analysis was carried out using SPSS software Version 16. The results of lipid tests, antioxidant, and lipid peroxidation status markers were expressed in Mean ± SD. The collected data was scrutinized with student’s t-test to evaluate the difference between the patients and controls. p values ≤ 0.05 were considered statistically significant.
Results

There was a statistically significant reduction in the mean serum (SOD) superoxide dismutase levels in moderate and severe psoriasis groups when compared to the control group \((p < 0.004)\). Whereas a statistically significant increase was noted in the mean serum malondialdehyde assay (MDA) levels in mild, moderate, and severe psoriasis groups in contrast to controls \((p < 0.01)\). The same can be seen in Figure 1.

Comparison of Lipid Profile among Psoriatic Patients and Healthy individuals as Controls

The mean ± SD serum total cholesterol level of the severe psoriasis group was found to be significantly elevated when compared with the control group and mild psoriasis and moderate psoriasis groups \((p < 0.01)\). The mean ± SD serum triglyceride levels were markedly raised in the severe psoriasis group as compared with the control group, mild psoriasis group, and moderate psoriasis groups \((p < 0.01)\). The mean ± HDL-c levels were notably reduced in the severe psoriasis group in comparison with the control group, mild psoriasis, and moderate psoriasis groups \((p < 0.005)\). The mean ± SD LDL-C levels were significantly raised in the severe psoriasis group when matched with the control group, mild psoriasis group, and moderate psoriasis groups \((p < 0.005)\).

| Table 1: Comparison of Biochemical Variables among the Study Population |
|---------------------------------------------------------------|
| Variables          | Controls \((n=50)\) | Psoriatic Patients |
|                   | Mean ± SD         | Mean ± SD         | Mean ± SD         | Mean ± SD         |
| Serum SOD (U/L)   | 109.2 ± 32.7      | 92.4 ± 31.7       | 89.5 ± 25*        | 84.8 ± 35*        |
| Serum MDA (nmol/mL)| 10.6 ± 2.8        | 11.3 ± 2.3        | 13.3 ± 2.8        | 29.8 ± 14.4       |

\* Statistically highly significant as compared to Controls \(p < 0.004\)
\○ Statistically significant as compared to Mild Psoriasis \(p < 0.05\)
\▲ Statistically significant as compared Moderate Psoriasis \(p < 0.05\)
\◆ Statistically significant as compared to Severe Psoriasis \(p < 0.01\)

Figure 1: Comparison of Serum SOD, MDA among the Control & Patient Groups

Table 2: Comparison of Lipid Profile among the Study Population

| Variable | Controls \((n=50)\) | Psoriatic Patients |
|----------|---------------------|--------------------|
|          | Mean ± SD          | Mean ± SD          | Mean ± SD          |
| Cholesterol | 147.5 ± 27.7      | 151.5 ± 36         | 193 ± 42.7        | 235.1 ± 35*\▲ |
| Triglyceride | 104.4 ± 25        | 129 ± 19.8         | 136.8 ± 29.1      | 160.1 ± 25*\▲ |
| HDL-c    | 36.3 ± 4.8         | 32 ± 8.5           | 26.6 ± 15.8       | 21.7 ± 5.9 *\▲ |
| LDL-c    | 91.4 ± 30.4        | 99.7 ± 28.9        | 104.2 ± 30.4      | 125 ± 33*\▲ |

\* Statistically significant as compared to Controls \(p < 0.05\)
\○ Statistically significant as compared to Mild Psoriasis \(p < 0.005\)
\▲ Statistically significant as compared Moderate Psoriasis \(p < 0.05\)
\◆ Statistically significant as compared to Severe Psoriasis \(p < 0.01\)
Lipid peroxidation can be determined through various methods as ROS provoke oxidation of polyunsaturated fatty acids (PUFA) in the biological system which can be measured with lipid peroxidation markers like MDA, Glutathione, and SOD. In psoriasis, it has been investigated by various researchers and almost all are in agreement that this stress affects all patients irrespective of their age, length, and severity of the disease, diet, and BMI, etc. whereas total antioxidant status in psoriatic patients indicates the aggravation of the disease. In this study, we found a significant increase in mean serum MDA levels in psoriatic patients when compared to controls ($p<0.05$), mainly because lipid peroxidation, is implicated in the pathogenesis of psoriasis. Similar findings have been suggested by national and international studies e.g. Nast A, et al. (2015)\textsuperscript{1} elaborated this trend of increased serum MDA levels in psoriatic patients as compared to controls. In another study, Elhaddad and colleagues (2017) observed some disturbances in the serum levels of trace elements and total antioxidant status of patients with psoriasis.\textsuperscript{11}

In our study, we have also established a positive correlation between serum MDA levels and the progression of the disease. The possible mechanism of the increased MDA levels in oxidative stress might be due to the increased ROS activity of Phospholipase A\textsubscript{2} causing peroxidation of Arachidonic acid with the help of mediators that lead to increased production of MDA. In contrast to our findings, Augustin et al. (2016)\textsuperscript{12} reported no remarkable dissimilarity in serum MDA levels among psoriatic cases and controls.

In our study, mean SOD levels were found to be significantly lower in psoriatic patients in contrast to controls ($p<0.05$). These results correlate with the findings of previous studies like (Mawla et al. (2013))\textsuperscript{13}. Lower levels of antioxidant SOD were observed in psoriatic patients particularly in the severe psoriasis category. The reason for lower levels of antioxidant SOD could be due to its utilization in reducing the inflammatory markers. In contradiction to our study, Menter et al., (2008)\textsuperscript{14} found no significant variation in serum SOD levels between psoriatic cases and controls.

On evaluating the lipid profile, we found a significant elevation in mean total cholesterol levels in psoriatic patients when compared to controls ($p<0.05$). Similar findings were reported by Latha and Kumar (2014)\textsuperscript{15} Bhatia et al., (2014)\textsuperscript{16} and Khan et al., (2017).\textsuperscript{17} We also found a significant elevation in the mean triglyceride levels in psoriatic patients when compared to controls ($p<0.05$); Ghafour et al., (2015)\textsuperscript{18} reported similar results although Arora et al., (2015)\textsuperscript{19} found no significant difference in triglyceride levels among psoriatic patients when compared to controls.

Our study also showed a significant reduction in mean HDL-c levels in psoriatic patients when compared to controls ($p<0.05$). This finding has been supported by Arora et al., (2015)\textsuperscript{19} and Augstin et al., (2016)\textsuperscript{12}, whereas Dsouza and Kuruville (2013)\textsuperscript{20} reported no significant difference in HDL-c levels among psoriatic patients and controls. Mean LDL-c levels in psoriatic patients were found to be significantly elevated in our study when compared to controls ($p<0.05$). This finding has been supported by Arora et al., (2015)\textsuperscript{19}, and Bhatia and coworkers (2014)\textsuperscript{16} while other studies such as Latha and colleagues (2014)\textsuperscript{15} found no significant difference in LDL-c levels between psoriatic patients and controls. And the same was reported in another study.\textsuperscript{21}

## Conclusion

In conclusion, the results of this study showed that an imbalance in the oxidant/antioxidant status might be implicated in the pathogenesis of psoriasis. In addition, the findings of this study support the previous research studies in concluding that hyperlipidemia is markedly more common in psoriasis patients as compared to their healthy control counterparts in the community. Both these factors may
lead to the development of atherosclerosis with all its complications.

**Recommendations**

Based on these findings, it is recommended that early detection and management of hyperlipidemia should be considered in psoriasis patients to avoid early or late complications. It will be effective in reducing the morbidity and mortality associated with the disease. Furthermore, based on the findings of this study, antioxidant supplementation is recommended to inactivate free radicals. This could be highly effective in preventing further new epidermal destruction, thereby reducing the severity and progression of the disease.

**Source of Support**

Biochemical kits provided by Basic Medical Sciences Institute (BMSI) Jinnah Postgraduate Medical Centre (JPMC), Karachi-75510.

**References**

1. Gisondi P, Del Gigiò M, Girolomoni G. Considerations for systemic treatment of psoriasis in obese patients. American journal of clinical dermatology. 2016 Dec 1;17(6):609-15. https://doi.org/10.1007/s40257-016-0211-7
2. Tang MM, Chang CC, Chau IC, Heng A. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. International journal of dermatology. 2013 Mar;52(3):314-22. https://doi.org/10.1111/j.1365-4632.2011.03540.x
3. Samuel TV, Murari K. Potential role of oxidative stress and antioxidant deficiency in pathogenesis of psoriasis. Int J of Pharma and Bio Sciences 2013;4(3):1039-44.
4. Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta dermato-venerologica. 2012 May 15;92(3):299-303. DOI: https://doi.org/10.2340/00015555-1273
5. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. Journal of allergy and clinical immunology. 2014 Feb 1;133(2):429-38. https://doi.org/10.1016/j.jaci.2013.07.049
6. Nast A, Jacobs A, Rosueneck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. Journal of Investigative Dermatology. 2015 Nov 1;135(11):2641-8. https://doi.org/10.1038/jid.2015.206
7. Shalom G, Zisman D, Bittermann H, Harman-Boehm I, Greenberg- Dotan S, Dreilher J, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500 000 person-year study. JAMA dermatology. 2015 May 1;151(5):533-8. doi:10.1001/jamadermatol.2014.4956
8. Ramos-e-Silva M, Jacques CD. Epidermal barrier function and systemic diseases. Clinics in dermatology. 2012 May 1;30(3):277-9. https://doi.org/10.1016/j.clindermatol.2011.08.025
9. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013 Feb 1;133(2):377-85. https://doi.org/10.1038/jid.2012.339
10. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug design, development and therapy. 2013;7:201. DOI: 10.2147/DDDT.S32713
11. Elhaddad H, Morsy R, Mourad B, Elnimr T. A comprehensive study on the content of serum trace elements in psoriasis. Journal of Elementology. 2017 Mar 1;22(1):31-42. DOI 10.5601/jelem.2015.20.3.997
12. Augustin M, Krüger K, Radtke MA, Schwippel I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216(4):366-72. https://doi.org/10.1159/000119415
13. Abdel-Mawla MY, Nofal E, Khalifa N, Abdel-Shakoor R, Nasr M. Role of oxidative stress in psoriasis: An evaluation study. J Am Sci. 2013;9:151-5.
14. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section I. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2008 May 1;58(5):826-50. https://doi.org/10.1016/j.jaad.2008.02.039
15. Latha KP, Kumar A. Serum lipids and lipoprotein (a) levels in psoriasis. Intern J Sci Res. 2014; 8:283-284.
16. Bhattacharya K, Malpani S, Singh A, Sadheer Z, Kosta S, Kumar R. Lipid profile in psoriasis: A case control study. Intern J Bioassays 2014; 3:182-182.
17. Khan F, Naeem MS, Ahmad Z, Zuberi AN. Comparison of Serum Zinc and Copper levels in Psoriatic patients of local population. Journal of Saidu Medical College 2017;7(2):72-74.
18. Ghafoor R, Rashid A, Anwar MI. Dyslipidemia and psoriasis: a case control study. Journal of the College of Physicians and Surgeons Pakistan. 2015 May 1;25(5):324-7.
19. Arora M, Kumar S, Mahat RK, Shrama A, Mustafa I. Study of lipid profile and paraoxonase-1 activity in psoriatic patients. Intern J Biomedical Advance Res 2015; 6:145-148.
20. Dsooua PH and Kuruville M. Dyslipidemia in psoriasis: as a risk for cardiovascular disease. Intern J Res Med Sci. 2013; 1:53-57.
21. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007 Jul 21;370(9583):263-71. https://doi.org/10.1016/S0140-6736(07)61128-3